[The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
Etofibrate retard administered in a daily dose 500 mg to 14 outpatients with hyperlipoproteinemia type IIa decreased the cholesterol only 1.7% after a treatment period of 6 weeks. After a treatment of 12 weeks the serum cholesterol was higher in 10 of the 14 patients than in the pretreatment period. Of low grade was the effect of etofibrate retard in 6 patients with type IIb or IV. The triglycerides decreased from 564 mg/dl to 455 mg/dl in the mean. The effect of this double ester from clofibrinic and nicotinic acid (59% to 41%) is uncertain in HLP type IIa, IIb and IV in the recommended dose of 500 mg/day.
D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D009539:Nicotinic Acids; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate
Zur Wirkung von Etofibrat auf Cholesterin- und Triglyceridwerte im Serum.